Fractional Chief Medical Officer
Board-certified pathologist-level clinical leadership, quality systems expertise, and multi-professional organizations leadership experience with broad network access — without the cost or constraints of a full-time executive hire.
WHAT YOU GET
01
Pathology ecosystem knowledge
AP/CP board-certified with deep diagnostic and laboratory medicine expertise across clinical, surgical and cytopathology, quality systems, and clinical operations.
ENGAGEMENT TIERS
01
Advisory Tier 1
4–6 hours / month
Monthly strategic call, async availability, clinical claims review, and named Clinical Advisor on company materials. Ideal for early-stage companies seeking credibility and occasional expert input.
02
Multi-professional organizations leadership experience
Active presence in pathology professional organizations, with established relationships across the global pathology community.
03
Regulatory literacy
FDA clinical evidence strategy, CLIA/CAP accreditation advisory, predicate device identification, and U.S. market entry guidance for diagnostic technologies.
04
Consulting platform
Established practice in pathology leadership, quality systems, and executive development through Sirgi Consulting.
02
Advisory Tier 2
10–15 hours / month
Defined deliverables across clinical strategy, regulatory evidence advisory, KOL introductions, pathology workflow review, and event representation. Named CMO on leadership page and materials. Best for medtech and digital pathology companies preparing for U.S. market entry, fundraising, or FDA engagement.
WHO IS THIS FOR
-
Digital pathology and AI companies
-
European MedTech entering the U.S. market
-
Diagnostics and CRO organizations
-
Lab automation and quality software
-
Biopharma companion diagnostics
-
Reference labs building AI programs
03
Fractional Chief Medical Officer
20–30 hours / month
All Fractional CMO deliverables plus advisory board participation, investor presentations, international pathology organization representation, clinical publication review, and ongoing regulatory strategy. Best for companies at inflection points — Series A/B, FDA submission preparation, or U.S. commercial launch.